GlassScriptPhysician profile
Brooke Ruane
NPI 1154895241
$2,833.17
in general payments reported to CMS, 2019-2025
14 companies · $1,639 in 2025
The $1,639 reported for 2025 was more than what 93% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $243 · 2022: $163 · 2023: $569 · 2024: $219 · 2025: $1,639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,401 · Consulting Fee: $900 · Education: $79.99 · Travel and Lodging: $45.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,400.95 |
| Consulting Fee | $900.00 |
| Education | $79.99 |
| Travel and Lodging | $45.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,734.01 | 2021-2025 | Nucala, Trelegy Ellipta |
| Pulmonx Corporation | $246.81 | 2023-2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Genzyme Corporation | $137.70 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $126.03 | 2023-2025 | Fasenra |
| Insmed, INC. | $126.03 | 2023-2024 | Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.92 | 2022-2024 | Ofev, Combivent Respimat, Spiriva Respimat |
| Regeneron Healthcare Solutions, INC. | $99.05 | 2023-2025 | Dupixent |
| Bayer Healthcare Pharmaceuticals INC. | $63.07 | 2022-2023 | |
| Baxter Healthcare | $42.83 | 2022 | |
| Electromed, INC. | $29.69 | 2022-2023 | Smartvest |
| Actelion Pharmaceuticals US, INC. | $28.56 | 2025 | Opsumit, Uptravi |
| Verona Pharma, INC. | $28.29 | 2025 | Ohtuvayre |
| Averitas Pharma INC. | $27.97 | 2025 | Qutenza |
| Sanofi Pasteur INC. | $27.21 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Ruane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.